Physician profile
Ryan W Shao
NPI 1649406190
$1,346.57
in general payments reported to CMS, 2019-2025
31 companies · $199 in 2025
The $199 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $888 · 2022: $24.72 · 2023: $21.00 · 2024: $214 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $391 · Education: $43.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $390.60 |
| Education | $43.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $156.47 | 2024-2025 | Assure Wcd |
| Abbott Laboratories | $142.30 | 2025 | Cardiomems |
| Novartis Pharmaceuticals Corporation | $90.83 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $78.12 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $69.15 | 2019 | |
| Genentech USA, INC. | $68.06 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $64.61 | 2019 | |
| Amgen INC. | $60.26 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.04 | 2019 | |
| Pfizer INC. | $58.28 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $56.59 | 2019 | |
| Janssen Pharmaceuticals, INC | $44.03 | 2019-2024 | Rybrevant |
| Exelixis INC. | $38.97 | 2019-2022 | |
| Janssen Biotech, INC. | $37.86 | 2019 | |
| Astellas Pharma US INC | $37.42 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $32.99 | 2024 | Carto 3 |
| Puma Biotechnology, INC. | $29.72 | 2019 | |
| Celgene Corporation | $28.30 | 2019 | |
| Agios Pharmaceuticals, INC. | $27.28 | 2019 | |
| Lantheus Medical Imaging, INC. | $23.02 | 2024 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Tolmar Pharmaceuticals, INC. | $15.71 | 2019 | |
| Caris Mpi, INC. | $14.87 | 2025 | Mi Cancer Seek |
| Gilead Sciences, INC. | $14.45 | 2019 | |
| Tesaro, INC. | $14.17 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.46 | 2019 | |
| Incyte Corporation | $12.43 | 2019 | |
| Foundation Medicine, INC. | $12.41 | 2019 | |
| Lilly USA, LLC | $12.07 | 2019 | |
| Seagen INC. | $11.70 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Shao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.